NUVATION BIO TO EXPAND PIVOTAL PHASE 3 SIGMA STUDY OF SAFUSIDENIB FOR IDH1-MUTANT GLIOMA TO SIX EUROPEAN COUNTRIES

Reuters · 4d ago

Please log in to view news